Latest Breaking News On - Vitamink antagonist - Page 1 : comparemela.com

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Matthew szotRobert blumPrnewswire cadrenal therapeutics incCadrenal therapeutics incLytham partnersVirtual healthcare equity conferenceNoble capital marketsInvestor relationsVitamink antagonist

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

/PRNewswire/ Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible.

Robert blumMatthew szotPrnewswire cadrenal therapeutics incCadrenal therapeutics incLytham partnersVirtual healthcare equity conferenceNoble capital marketsInvestor relationsVitamink antagonist

Cadrenal Therapeutics (CVKD) Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Cadrenal Therapeutics (CVKD) Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesQuang phamEspero biopharmaJeff coleCadrenal therapeutics incUniversity of southern californiaLegacy pharmaceuticalsBausch health companiesValeant pharmaceuticals internationalCorporate developmentUniversity of michiganCadrenal therapeuticsVitamink antagonistChief operatingBoard directorChief financial officer

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ Cadrenal Therapeutics, Inc. , a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist for unmet needs in anticoagulation .

United statesJeff coleMatthew szotEspero biopharmaRobert blumQuang phamLytham partnersCadrenal therapeutics incUniversity of michiganBausch health companiesUniversity of southern californiaCompany annual report on formLegacy pharmaceuticalsPrnewswire cadrenal therapeutics incValeant pharmaceuticals internationalCorporate development

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

PONTE VEDRA, Fla., Jan. 24, 2024 /PRNewswire/ Cadrenal Therapeutics, Inc., , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant designed to.

Douglas losordoRobert blumMatthew szotJoe pantginisPrnewswire cadrenal therapeutics incCadrenal therapeutics incCompany webcastHc wainwright coLytham partnersChief medical officerManaging directorVitamink antagonist